B. Vcelar

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
B Vcelar, Brigitta Vcelar, Brigitta A Vcelar, Brigitta A. Vcelar
Publication record
37 papers · 1,821 citations · H-index 22

PAPERS

Randomized, Double-Blind, Phase I Pharmacokinetic Study of Subcutaneous Recombinant Human Superoxide Dismutase (rhSOD) in Healthy Volunteers
20251 citationsauthor #7
Spinal Stroke: Outcome Attenuation by Erythropoietin and Carbamylated Erythropoietin and Its Prediction by Sphingosine-1-Phosphate Serum Levels in Mice
20221 citationsauthor #6
Intense Uptake of Liposomal Curcumin by Multiple Myeloma Cell Lines: Comparison to Normal Lymphocytes, Red Blood Cells and Chronic Lymphocytic Leukemia Cells
201912 citationsauthor #6
A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc™) in patients with locally advanced or metastatic cancer
2018112 citationsauthor #8
Pharmacokinetics of liposomal curcumin (Lipocurc™) infusion: effect of co-medication in cancer patients and comparison with healthy individuals
201825 citationsauthor #5
Distribution of Curcumin and THC in Peripheral Blood Mononuclear Cells Isolated from Healthy Individuals and Patients with Chronic Lymphocytic Leukemia.
201810 citationsauthor #6
Distribution and Metabolism of Lipocurc™ (Liposomal Curcumin) in Dog and Human Blood Cells: Species Selectivity and Pharmacokinetic Relevance.
201716 citationsauthor #5
Erythropoietin preconditioning improves clinical and histologic outcome in an acute spinal cord ischemia and reperfusion rabbit model.
201625 citationsauthor #3
In Vitro Study of a Liposomal Curcumin Formulation (Lipocurc™): Toxicity and Biological Activity in Synovial Fibroblasts and Macrophages.
201630 citationsauthor #4
Regulatory approval and a first-in-human phase I clinical trial of a monoclonal antibody produced in transgenic tobacco plants.
2015223 citationsauthor #21
Safety, tolerability and pharmacokinetics of liposomal curcumin in healthy humans.
2015117 citationsauthor #2
Comparison of pharmacokinetic and safety profiles between Bemfola® and Gonal-f® after subcutaneous application
201520 citationsauthor #7
MABGEL 1: First Phase 1 Trial of the Anti-HIV-1 Monoclonal Antibodies 2F5, 4E10 and 2G12 as a Vaginal Microbicide
201435 citationsauthor #7
Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques
2013162 citationsauthor #10
Effect of liposomal curcumin on red blood cells in vitro.
201316 citationsauthor #2
Abstract LB-165: Safety and pharmacokinetics of liposomal curcumin in healthy subjects:A randomized placebo-controlled double blind first-in human study.
20130 citationsauthor #3
The neuroprotective and neurorescue effects of carbamylated erythropoietin Fc fusion protein (CEPO-Fc) in a rat model of Parkinson's disease.
201332 citationsauthor #11
Carbamylated erythropoietin-FC fusion protein and recombinant human erythropoietin during porcine kidney ischemia/reperfusion injury
201332 citationsauthor #9
Infusion pharmacokinetics of Lipocurc™ (liposomal curcumin) and its metabolite tetrahydrocurcumin in Beagle dogs.
201230 citationsauthor #4
Non-neutralizing IgG anti-PID antibodies decreased viral load following high dose vaginal challenge of non-human primates
20120 citationsauthor #8
Non-neutralizing IgG anti-PID antibodies decreased viral load following high dose vaginal challenge of non-human primates
20120 citationsauthor #8
Human pharmacokinetics of intravenous recombinant human Cu/Zn superoxide dismutase.
20124 citationsauthor #7
The effect of erythropoietin on platelet and endothelial activation markers: A prospective trial in healthy volunteers
201218 citationsauthor #2
Tissue distribution of (Lipocurc™) liposomal curcumin and tetrahydrocurcumin following two- and eight-hour infusions in Beagle dogs.
201233 citationsauthor #4
Comparison of carbamylated erythropoietin-FC fusion protein and recombinant human erythropoietin during porcine aortic balloon occlusion-induced spinal cord ischemia/reperfusion injury
201137 citationsauthor #4
Adjunctive Passive Immunotherapy in Human Immunodeficiency Virus Type 1-Infected Individuals Treated with Antiviral Therapy during Acute and Early Infection
2007137 citationsauthor #2
Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data
200753 citationsauthor #1
Long-Term Multiple-Dose Pharmacokinetics of Human Monoclonal Antibodies (MAbs) against Human Immunodeficiency Virus Type 1 Envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5)
200677 citationsauthor #8
Liposomal recombinant human superoxide dismutase for the treatment of Peyronie's disease: a randomized placebo-controlled double-blind prospective clinical study.
200563 citationsauthor #5
937: Liposomal Recombinant Human Superoxide Dismutase for the Treatment of Peyronie's Disease: A Randomized Placebo-Controlled Double-Blind Clinical Study
20050 citationsauthor #6
865Liposomal recombinant human superoxide dismutase for the treatment of peyronie's disease: A randomized placebo-controlled double-blind clinical study
20050 citationsauthor #6
Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12.
2004119 citationsauthor #3
Live cold-adapted influenza A vaccine produced in Vero cell line.
200436 citationsauthor #4
Neutralization Profiles of Newly Transmitted Human Immunodeficiency Virus Type 1 by Monoclonal Antibodies 2G12, 2F5, and 4E10
200498 citationsauthor #5
Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation
2002107 citationsauthor #3
A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1
2002128 citationsauthor #3
Pilot Study on Liposomal Recombinant Human Superoxide Dismutase for the Treatment of Peyronie’s Disease
200114 citationsauthor #4

TIMELINE

2001 14 citations

2002 235 citations

2004 253 citations

2005 63 citations

2006 77 citations

2007 190 citations

2011 37 citations

2012 85 citations

2013 242 citations

2014 35 citations

2015 360 citations

2016 55 citations

2017 16 citations

2018 147 citations

2019 12 citations

2022 1 citations

2025 1 citations

B. Vcelar

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT